Peptide therapeutics: current status and future directions

Padhi, 2014, Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects, Tuberculosis, 94, 363, 10.1016/j.tube.2014.03.011 Buchwald, 2014, Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: implications for ileal transposition, Surg. Obes. Relat. Dis., 10.1016/j.soard.2014.01.032 Giordano, 2014, Neuroactive peptides as putative mediators of antiepileptic ketogenic diets, Front. Neurol., 5, 63, 10.3389/fneur.2014.00063 Robinson, 2014, Diversity of conotoxin gene superfamilies in the venomous snail, Conus victoriae, PLOS ONE, 9, e87648, 10.1371/journal.pone.0087648 Kaspar, 2013, Future directions for peptide therapeutics development, Drug Discov. Today, 18, 807, 10.1016/j.drudis.2013.05.011 Transparency Market Research, 2012 Sheridan, 2012, Proof of concept for next-generation nanoparticle drugs in humans, Nat. Biotechnol., 30, 471, 10.1038/nbt0612-471 Steidler, 2009, Actobiotics as a novel method for cytokine delivery, Ann. N. Y. Acad. Sci., 1182, 135, 10.1111/j.1749-6632.2009.05067.x Schulte, 2005, Peptides in body fluids and tissues as markers of disease, Expert Rev. Mol. Diagn., 5, 145, 10.1586/14737159.5.2.145 Manning, 2010, Stability of protein pharmaceuticals: an update, Pharm. Res., 27, 544, 10.1007/s11095-009-0045-6 Hamley, 2007, Peptide fibrillization, Angew. Chem. Int. Ed. Engl., 46, 8128, 10.1002/anie.200700861 Riber, 2013, A novel glucagon analogue, ZP-GA-1, displays increased chemical and physical stability in liquid formulation, Diabetes, 62, A99 Larsen, B. et al. Zealand Pharma A/S. Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis. US 6,528,486 B1, WO 99/46283 Timmerman, 2009, Functional reconstruction of structurally complex epitopes using CLIPSTM technology, Open Vaccine J., 2, 56, 10.2174/1875035400902010056 Houston, 1996, Lactam bridge stabilization of alpha-helices: the role of hydrophobicity in controlling dimeric versus monomeric alpha-helices, Biochemistry, 35, 10041, 10.1021/bi952757m Sim, 2012, Directional assembly of alpha-helical peptides induced by cyclization, J. Am. Chem. Soc., 134, 20270, 10.1021/ja3098756 Knudsen, 2010, Liraglutide: the therapeutic promise from animal models, Int. J. Clin. Pract. Suppl., 4, 10.1111/j.1742-1241.2010.02499.x Bao, 2013, Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat, Cardiovasc. Diabetol., 12, 148, 10.1186/1475-2840-12-148 Delgado, 1992, The uses and properties of PEG-linked proteins, Crit. Rev. Ther. Drug Carr. Syst., 9, 249 Henry, 2014, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, J. Diabetes Complicat., 28, 393, 10.1016/j.jdiacomp.2013.12.009 Hattori, 2009, The human intestinal microbiome: a new frontier of human biology, DNA Res., 16, 1, 10.1093/dnares/dsn033 Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 Fosgerau, 2011, The new glucagon-GLP-1 dual agonist ZP2929 in combination with long-acting insulin improves glycemic control without causing weight loss in db/db mice, Diabetes, 60, A408 Finan, 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci. Transl. Med., 5, 209ra151, 10.1126/scitranslmed.3007218 Fosgerau, 2013, The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab., 15, 62, 10.1111/j.1463-1326.2012.01676.x Just, 2014, The novel GLP-1-GLP-2 dual agonist ZP-GG-72 increases intestinal growth and improves insulin sensitivity in DIO mice, Diabetes, 63, A1 Pocai, 2012, Unraveling oxyntomodulin, GLP1's enigmatic brother, J. Endocrinol., 215, 335, 10.1530/JOE-12-0368 Gault, 2013, A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice, J. Biol. Chem., 288, 35581, 10.1074/jbc.M113.512046 DiMarchi, R.D. et al. Hoffmann–La Roche Inc. Analogs of glucagon exhibiting GIP receptor activity. PCT/US2013/046229, WO/2013/192130 Zhou, 2014, Functional selectivity of GPCR signaling in animals, Curr. Opin. Cell Biol., 27, 102, 10.1016/j.ceb.2013.11.010 Okarvi, 2008, Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer, Cancer Treat. Rev., 34, 13, 10.1016/j.ctrv.2007.07.017